Venture debt fund research profile
InnoVen Capital is an Asia-wide venture-lending platform backed through Seviora, a Temasek subsidiary, and UOB. In India it operates across venture-backed companies from early growth through pre-IPO, combining medium-term loans with founder-friendly underwriting, follow-on capacity and an equity kicker where a borrower achieves a liquidity event.
At a glance
Research profile
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
InnoVen Capital (Temasek/Seviora) uses a venture debt approach across Venture debt, growth-stage technology, healthcare.
Current evidence
InnoVen’s India platform remains active under the Seviora/Temasek and UOB-backed Asia platform. The manager’s January 2026 Startup Outlook Report and current India site continue to describe venture debt from seed through pre-IPO, with more than $1B invested across 235+ Indian portfolio companies; its current India portfolio and team pages provide named borrowers and leadership. Fund-by-fund capacity, fees/carry and India-only returns remain not publicly disclosed.
Strategy
Venture debt
Sector focus
Venture debt, growth-stage technology, healthcare
AIF structure context
Indian private credit, venture-debt and special-situations funds are commonly structured as Category II AIFs. Verify the specific vehicle and registration before investing.
Current signal
InnoVen’s India platform remains active under the Seviora/Temasek and UOB-backed Asia platform. The manager’s January 2026 Startup Outlook Report and current India site continue to describe venture debt from seed through pre-IPO, with more than $1B invested across 235+ Indian portfolio companies; its current India portfolio and team pages provide named borrowers and leadership. Fund-by-fund capacity, fees/carry and India-only returns remain not publicly disclosed.
Investor questions
InnoVen Capital (Temasek/Seviora) is covered in Rupeia's private credit research universe. The current public record describes the strategy as Venture debt, with a sector focus of Venture debt, growth-stage technology, healthcare. The profile should be read with the linked source trail and Typical route: Category II AIF context.
The profile displays only company or asset names attributable to InnoVen Capital (Temasek/Seviora) in the reviewed public sources: Cure.fit; PharmEasy; OfBusiness; Infra.Market; Zetwerk; Eruditus; Swiggy; FirstCry. It does not represent a complete current portfolio unless the manager has published one.
The India platform says almost one-third of its portfolio companies returned for follow-on debt, while the wider group reports 770+ debt transactions and 50+ unicorns. These are platform-level manager disclosures, not an audited fund-return history. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
Public fund size: The India platform publicly reports more than $1 billion invested across 235+ companies; a 2021 report described a proposed independent India debt fund of about $200 million, but the final structure was not verified.. Public terms or access information: The manager describes medium-term loans with fixed rates and fees, generally monthly repayment, no mandated end use, and an equity kicker in successful IPO or buyout cases; it does not normally take board seats.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
The current source record names Ashish Sharma (Managing Partner, InnoVen Capital India); Tarana Lalwani (Partner, InnoVen Capital India). Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
Review borrower concentration, security and seniority, cash versus accrued income, defaults, recoveries, fund leverage and liquidity. The current open diligence point is: Current India fund-by-fund structure, capacity, fees/carry, realized loss history and India-only returns remain not publicly disclosed; platform-level Asia metrics are not treated as India fund performance..
2026-01-23: InnoVen’s India platform remains active under the Seviora/Temasek and UOB-backed Asia platform. The manager’s January 2026 Startup Outlook Report and current India site continue to describe venture debt from seed through pre-IPO, with more than $1B invested across 235+ Indian portfolio companies; its current India portfolio and team pages provide named borrowers and leadership. Fund-by-fund capacity, fees/carry and India-only returns remain not publicly disclosed.
Next step
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.